Johnson & Johnson and Merck will staff the Greenhouse headquarters with one business development employee each, spokesmen told news provider Pittsburgh Tribune Review.

Alongside Amunix in Versartis' B round are venture capital (VC) firms New Leaf Venture Partners Advent Venture Partners and Index Ventures.

In a regulatory filing, CalciMedica said it had raised $9.2m. Two-thirds of this money is released following a clinical milestone for its CM2489 once-daily oral therapeutic for patients with moderate-to-severe plaque psoriasis.

Joining Henrijette Richter, investment director at Novo, in the seed round is venture capital firm Sunstone Capital.

The Merck Global Health Innovation group is a limited liability company managing a fund of the same name looking to identify new business models and external opportunities in adjacent healthcare fields to its main medical areas, which include diabetes and vaccines.

Alongside Ascension Health Ventures in the D round consortium are venture capital firms Split Rock Partners, Legacy Life Sciences, EDF Ventures, MedVenture Associates, DFJ InCube Ventures, Emergent Medical Partners and Asset Management Partners.

Canada-based venture capital firm AgeChem led the B round, which included participation by existing investors Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.

Taj Pharmaceuticals sets up corporate venturing fund as Eli Lilly co-invests in Mirror Projects and GlaxoSmithKline links with academia.

Fluidigm raised $75m at $13.50 per share by selling 5.6 million shares, with a further 833,750 available if demand is strong enough for its investment banks Deutsche Bank and Piper Jaffray, according to its regulatory filing.

AcelRx had planned to raise $86m in its initial public offering (IPO) but is now offering eight million shares at $5 each, with a further 1.2 million available if there is enough demand, according to its regulatory filing.